Therefore, our results suggest that combined treatment with GSK-3β inhibitor and conventional chemotherapy may be a promising approach to overcome environment-mediated drug resistance and for the treatment of EndMT-related disorders in lung cancer. This evidence concerns the gene GSK3B and lung cancer.